Cardior Pharmaceuticals GmbH announced that it has received €64 million in its series B round of funding led by new investor INKEF Netherlands Manager B.V. on August 25, 2021. The transaction included participation from new investors Fund+ NV, Coparion GmbH & Co. KG, Hadean Ventures, Sunstone Capital A/S, returning investors Life Sciences Partners BV, BioMedPartners AG, Bristol-Myers Squibb Company and High-Tech Gründerfonds Management GmbH. The transaction was oversubscribed. As part of the transaction, the representatives from INKEF Netherlands Manager B.V, Fund+ NV and Sunstone Capital A/S will join the company’s advisory board .